comparemela.com

Latest Breaking News On - Grand pharmaceutical group limited - Page 2 : comparemela.com

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase.

United kingdomUnited statesTelix asia pacificCdx illuccixKyahn williamsonCorporate communicationsHealth canadaTelix pharmaceuticalsZhongnan hospital of wuhan universityTelix pharmaceuticals limited disclosure committeeEuropean unionPrnewswire telix pharmaceuticals limitedDrug administrationAustralian therapeutic goods administrationGroup limited grand pharmaAustralian securities exchange

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the imaging of prostate cancer using positron emission tomography (PET).

United statesUnited kingdomKyahn williamsonTelix asia pacificHealth canadaCorporate communicationsTelix pharmaceuticalsTelix pharmaceuticals limited disclosure committeeZhongnan hospital of wuhan universityEuropean unionGroup limited grand pharmaAustralian therapeutic goods administrationDrug administrationAustralian securities exchangeUnited states foodGreater china

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase.

United kingdomUnited statesCdx illuccixKyahn williamsonTelix asia pacificTelix pharmaceuticalsCorporate communicationsHealth canadaDrug administrationAustralian therapeutic goods administrationGroup limited grand pharmaAustralian securities exchangeZhongnan hospital of wuhan universityTelix pharmaceuticals limited disclosure committeeEuropean unionPrnewswire telix pharmaceuticals limited

Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow

/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow report and accompanying.

United statesUnited kingdomBruxelles capitaleTelix illuccixDedicaid gmbhCdx illuccix clinicaltrialsKyahn williamsonDedicaid gmbMerck kgaTelix pharmaceuticalsTelix pharmaceuticals limitedHealth canadaGroup limited grand pharmaDrug administrationAccess programEuropean union

OncoSec Medical Incorporated : Bankruptcy - Form 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT . | June 14, 2023

United statesBritish virgin islandsLinda shiStephany fosterChao zhouH kim lyerlyJoon kimKevin smithCompany board of directorsOncosec medical australia pty ltdOncosec medical incorporatedBankruptcy courtSecurities exchangeGroup limitedBankruptcy court onUnited states bankruptcy court

vimarsana © 2020. All Rights Reserved.